08-Jul-16 As a part of the company’s commitment to the health and life sciences industries, Celanese Corporation, a global technology and specialty materials company, will participate in the 2016 Controlled Release Society (CRS) Annual Meeting and Exposition. During the conference, Celanese will highlight VitalDose® ethylene vinyl acetate (EVA), a versatile polymer used in delivering controlled release medications with varying routes of administration including subcutaneous drug delivery implants.
Celanese VitalDose® EVA is a customizable, controlled release material that is meeting the growing needs of the industry as pharmaceutical companies look to create new routes of administration to improve efficacy and increase patient drug compliance.
“There’s more to pharmaceuticals than the drug itself. A reliable and safe method for releasing certain medications is critical to the medications’ effectiveness,” said Kelsey Achenbach, strategic marketing manager for EVA polymers at Celanese. “We have poured decades of experience into engineering VitalDose® EVA so manufacturers have a customizable polymer that gives them the flexibility to develop controlled release devices that can be used for external or subcutaneous applications.”
Celanese engineers designed VitalDose® EVA with properties that allow manufacturers to customize release rate of drugs used in implantable drug delivery devices. This copolymer blends well with other polymers so it can be used alone or with other excipients or additives to achieve the desired release rate. Pharmaceutical companies use VitalDose® EVA in a wide range of drug delivery applications including transdermal, subcutaneous, ocular, intravaginal, intraoral and rectal. A Celanese pharmaceutical product expert will deliver a poster presentation during the CRS conference that explores how processing techniques can affect pharmaceutical mechanical properties and potentially impede processability.
Previous News
Next News
{{comment.DateTimeStampDisplay}}
{{comment.Comments}}